29TA Stock Overview
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
TherapeuticsMD, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.75 |
| 52 Week High | US$34.75 |
| 52 Week Low | US$0.11 |
| Beta | 1.43 |
| 1 Month Change | 0% |
| 3 Month Change | 1.56% |
| 1 Year Change | -67.50% |
| 3 Year Change | -94.13% |
| 5 Year Change | -95.37% |
| Change since IPO | -95.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 29TA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.3% | 1.1% |
| 1Y | -67.5% | -28.6% | 1.9% |
Return vs Industry: 29TA underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 29TA underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 29TA volatility | |
|---|---|
| 29TA Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 29TA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 29TA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 416 | Brian Bernick | www.therapeuticsmd.com |
TherapeuticsMD, Inc. operates as a women’s healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation.
TherapeuticsMD, Inc. Fundamentals Summary
| 29TA fundamental statistics | |
|---|---|
| Market cap | €58.33m |
| Earnings (TTM) | -€27.21m |
| Revenue (TTM) | €92.29m |
0.6x
P/S Ratio-2.1x
P/E RatioIs 29TA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 29TA income statement (TTM) | |
|---|---|
| Revenue | US$91.98m |
| Cost of Revenue | US$19.62m |
| Gross Profit | US$72.36m |
| Other Expenses | US$99.48m |
| Earnings | -US$27.12m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.86 |
| Gross Margin | 78.67% |
| Net Profit Margin | -29.49% |
| Debt/Equity Ratio | -348.3% |
How did 29TA perform over the long term?
See historical performance and comparison